Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GSK Pharma to optimise...

    GSK Pharma to optimise product portfolio to drive growth in India

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-24T09:19:25+05:30  |  Updated On 17 Aug 2021 12:20 PM IST

    GSK is also looking to launch some new products in the country over the next 15 months as it adopts a more structured approach to engage trade channel partners, with a dedicated team to engage stockists and retailers across India.


    New Delhi: GlaxoSmithKline (GSK) pharmaceuticals is optimising its product portfolio with a focus on key brands to accelerate growth in India, a senior company official said. The company is also looking to launch some new products in the country over the next 15 months as it adopts a more structured approach to engage trade channel partners, with a dedicated team to engage stockists and retailers across India.


    "The business has embarked on it new strategy this year, as we put in place an optimal commercial structure and worked at building capability," GSK Pharmaceuticals MD (India) A Vaidheesh told.


    Read Also: GSK offers concessions to address Pfizer deal concerns


    "Our new commercial model is in place with an increased focus on our priority brands, and expansion in our field force to drive focus, including a new trade channel strategy," he added.


    Vaidheesh said GSK India has over 55 major brands in its portfolio and the company has chosen to focus on dermatology, anti-infectives, pain, hormones, respiratory, gastrointestinal, nutrition/vitamins and vaccines segments.


    In the past 12 months, the company has launched two new products -- Infanrix Hexa vaccine (6-in-1 combination DTaP vaccine) and Nucala (mepolizumab) in the respiratory segment.


    The new strategy has started yielding results, he said, adding that GSK Pharma's financial performance for Q3 highlighted the outcomes of this execution.


    Read Also: GSK eyes sale of $1.2 billion consumer health drugs; says report


    There was headline double-digit sales growth both for the quarter and year to date, underpinned by a strong volume delivery, Vaidheesh said.


    On new launches, he said, "Some of the products that we plan to launch in the next 12-15 months are Menveo (meningococcal vaccine), Fluarix Tetra (influenza vaccine) and Infanrix IPV (DTaP vaccine plus inactivated Polio)."

    A Vaidheeshanti infectivesDermatologyFluarix TetragastrointestinalGlaxoSmithKline PharmaceuticalsGSKGSK IndiaGSK PharmaceuticalshormonesIndiaInfanrix Hexa vaccineInfanrix IPVInfluenza Vaccinemeningococcal vaccineMenveoNucalaoptimisingpainpharmapharma newspharma news indiarespiratoryvaccinesvitamins
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok